August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
FDA Granted Breakthrough Therapy Designation for Treating NSCLC – BMS
Aug 23, 2025, 10:15

FDA Granted Breakthrough Therapy Designation for Treating NSCLC – BMS

Bristol Myers Squibb (BMS) shared a post on X:

“The FDA U.S. has granted Breakthrough Therapy Designation to our investigational EGFRxHER3 bispecific ADC for previously treated EGFR-mutant NSCLC.

Read More.”

More posts featuring Bristol Myers Squibb on OncoDaily